Moxifloxacin Hydrochloride是一种口服有效的 8-甲氧基喹诺酮类抗菌药物，可研究感染性肺炎，急性细菌性鼻窦炎和慢性支气管炎的急性细菌性加重。

Moxifloxacin is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.

在模拟人体疾病的小鼠体内,与用异烟肼/利福平/吡嗪酰胺相比,Moxioxacin结合RIF/吡嗪酰胺减少2个月的治疗时间.类似的,利福平/Moxioxacin/吡嗪酰胺一周两次处理小鼠,在4个月之后达到稳定治愈,而利福平/异烟肼/吡嗪酰胺每天处理一次,6个月后治愈.

Moxioxacin具有广谱的抗菌活性,对金黄色酿脓葡萄球菌,肺炎链球菌,化脓性链球菌,流感嗜血杆菌,H. parainuenzae,肺炎克雷伯菌,卡他莫拉菌,肺炎衣原体以及肺炎支原体表现出体外和临床活性。Moxioxacin通过诱捕DNA-药物-酶复合物发挥作用,其抑制了ATP依赖性的拓扑异构酶II（DNA促旋酶）和拓扑异构酶IV。

186826-86-8

C23H29ClFN3O4

437.89

莫西沙星盐酸盐;BAY12-8039 HCl;Moxifloxacin HCl;盐酸莫西沙星;BAY-128039

DMSO:88 mg/mL (200.96 mM)
H2O:15 mg/mL(34.3 mM)
Ethanol:<1 mgml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years